Each vial contains Ceftriaxone Sodium USP equivalent to Ceftriaxone 1 g and Tazobactam Sodium equivalent to Tazobactam 125 mg. Supplied with 10 ml Sterile Water for Injection.

Ritecef T Injection combines Ceftriaxone, a third-generation cephalosporin antibiotic, with Tazobactam, a β-lactamase inhibitor, to provide enhanced antibacterial activity against β-lactamase-producing organisms. This combination offers broad-spectrum bactericidal coverage and is effective in the treatment of community-acquired pneumonia and lower respiratory tract infections caused by susceptible bacterial pathogens.

Ritecef T Injection is indicated for the treatment of community-acquired pneumonia and lower respiratory tract infections caused by susceptible bacterial organisms.

Ceftriaxone is a third-generation cephalosporin antibiotic that exerts bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), resulting in bacterial cell lysis and death. Tazobactam is a penicillinate sulphone and β-lactamase inhibitor structurally related to sulbactam. It protects Ceftriaxone from enzymatic degradation by β-lactamase-producing bacteria, thereby extending its antibacterial spectrum and enhancing its therapeutic efficacy.

For adults and children over 12 years of age, the usual dose is 1–2 g once daily, or in equally divided doses twice daily depending on the severity of infection. In severe infections, 2–4 g daily is recommended, usually as a single dose every 24 hours. For neonates, the recommended dose is 20–50 mg/kg body weight once daily, not exceeding 50 mg/kg/day. For infants and children up to 12 years of age, the standard therapeutic dose is 50–75 mg/kg body weight once daily, or as directed by the treating physician.

Ritecef T Injection is contraindicated in patients with known hypersensitivity to β-lactam antibiotics. In patients with hypersensitivity to penicillin, the possibility of allergic cross-reactivity should be considered.